Costs of competing treatments for low-risk prostate cancer vary widely

Significant cost variations existed between competing treatments for low-risk prostate cancer from the time of diagnosis through treatment, according to the results of a time-driven activity-based costing analysis. The researchers noted that LDR brachytherapy remained significantly less costly than HDR brachytherapy ($8,978 vs. $11,448). Further, SBRT ($11,665) was less expensive than IMRT.
Healio